The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2020
Filed:
Feb. 02, 2006
Daniel A. Haber, Chestnut Hill, MA (US);
Daphne Winifred Bell, Chevy Chase, MD (US);
Jeffrey E. Settleman, Newton, MA (US);
Raffaella Sordella, Cold Spring Harbor, NY (US);
Nadia G. Godin-heymann, Stanmore, GB;
Eunice L. Kwak, Marlborough, MA (US);
Sridhar Krishna Rabindran, Eagleville, PA (US);
Daniel A. Haber, Chestnut Hill, MA (US);
Daphne Winifred Bell, Chevy Chase, MD (US);
Jeffrey E. Settleman, Newton, MA (US);
Raffaella Sordella, Cold Spring Harbor, NY (US);
Nadia G. Godin-Heymann, Stanmore, GB;
Eunice L. Kwak, Marlborough, MA (US);
Sridhar Krishna Rabindran, Eagleville, PA (US);
The General Hospital Corporation, Boston, MA (US);
Wyeth LLC, New York, NY (US);
Abstract
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.